Tonix Pharmaceuticals (TNXP)
NASDAQ:TNXP
| Dec 25 | Dec 24 | Mar 24 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 13.11M | $ 10.09M | $ 7.77M | $ 0.00 | $ 0.00 |
| Gross Profit | $ 6.47M | $ 2.33M | $ 3.03M | $ 0.00 | $ 0.00 |
| Operating Income | $ -125.70M | $ -136.70M | $ -118.38M | $ -112.09M | $ -92.31M |
| EBITDA | $ -123.78M | $ -74.32M | $ -114.09M | $ -110.84M | $ -92.26M |
| Net Income | $ -124.02M | $ -130.04M | $ -116.66M | $ -110.22M | $ -92.29M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 207.64M | $ 98.78M | $ 24.95M | $ 120.23M | $ 178.66M |
| Total Assets | $ 277.17M | $ 162.89M | $ 154.46M | $ 225.69M | $ 240.90M |
| Total Debt | $ 1.31M | $ 5.30M | $ 9.81M | $ 760.00K | $ 956.00K |
| Net Debt | $ -206.33M | $ -93.48M | $ -15.13M | $ -119.47M | $ -177.70M |
| Total Liabilities | $ 32.02M | $ 23.33M | $ 48.93M | $ 18.51M | $ 22.18M |
| Stockholders' Equity | $ 245.15M | $ 139.56M | $ 105.53M | $ 207.18M | $ 218.72M |
| Cash Flow | |||||
| Free Cash Flow | $ -103.21M | $ -61.05M | $ -109.90M | $ -146.20M | $ -110.86M |
| Operating Cash Flow | $ -99.84M | $ -60.92M | $ -102.00M | $ -98.05M | $ -75.56M |
| Investing Cash Flow | $ -4.53M | $ -120.00K | $ -29.07M | $ -48.15M | $ -35.31M |
| Financing Cash Flow | $ 214.53M | $ 134.87M | $ 36.52M | $ 87.84M | $ 212.49M |